标题
The role of bevacizumab in recurrent, platinum-sensitive ovarian cancer
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 14, Issue 10, Pages 1105-1113
出版商
Informa UK Limited
发表日期
2014-09-05
DOI
10.1586/14737140.2014.956095
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- A phase II evaluation of motesanib (AMG 706) in the treatment of persistent or recurrent ovarian, fallopian tube and primary peritoneal carcinomas: A Gynecologic Oncology Group study
- (2013) R.J. Schilder et al. GYNECOLOGIC ONCOLOGY
- Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours
- (2012) E Dean et al. BRITISH JOURNAL OF CANCER
- Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: A case–control study on survival in patients with two year follow-up
- (2012) Anna Fagotti et al. GYNECOLOGIC ONCOLOGY
- OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- (2012) Carol Aghajanian et al. JOURNAL OF CLINICAL ONCOLOGY
- 2010 Gynecologic Cancer InterGroup (GCIG) Consensus Statement on Clinical Trials in Ovarian Cancer
- (2011) Gavin C.E. Stuart et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
- At What Cost Does a Potential Survival Advantage of Bevacizumab Make Sense for the Primary Treatment of Ovarian Cancer? A Cost-Effectiveness Analysis
- (2011) David E. Cohn et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized, Double-Blind, Placebo-Controlled Phase II Study of AMG 386 Combined With Weekly Paclitaxel in Patients With Recurrent Ovarian Cancer
- (2011) Beth Y. Karlan et al. JOURNAL OF CLINICAL ONCOLOGY
- Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
- (2011) Robert A. Burger et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Phase 3 Trial of Bevacizumab in Ovarian Cancer
- (2011) Timothy J. Perren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials
- (2010) Vishal Ranpura et al. ACTA ONCOLOGICA
- Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis
- (2010) V. Ranpura et al. AMERICAN JOURNAL OF HYPERTENSION
- Which factors predict bowel complications in patients with recurrent epithelial ovarian cancer being treated with bevacizumab?
- (2010) D.L. Richardson et al. GYNECOLOGIC ONCOLOGY
- Bevacizumab Increases Risk for Severe Proteinuria in Cancer Patients
- (2010) S. Wu et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- Understanding and managing the possible adverse effects associated with bevacizumab
- (2009) S. S. Shord et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma
- (2009) John P. Diaz et al. GYNECOLOGIC ONCOLOGY
- Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis
- (2009) Sanjaykumar Hapani et al. LANCET ONCOLOGY
- The Future of Targeted Therapies in Ovarian Cancer
- (2009) S. Banerjee et al. ONCOLOGIST
- Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
- (2008) Halla S. Nimeiri et al. GYNECOLOGIC ONCOLOGY
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started